The company claims to be the second-largest private hospital chain in North India with a total capacity of 3,000 beds as of September 30, 2024. It also claims to be the largest private hospital chain in Haryana, with 1,600 beds spread across eight hospitals in the state. This scale allows the company to operate a sizeable network of NABH-accredited multi-speciality hospitals across four states.
The company has followed a cluster-based expansion approach by setting up hospitals in regions adjacent to its existing facilities. This strategy claims to enable resource sharing, operational efficiencies, and economies of scale. The approach has been used for both organic expansion and acquisition-driven growth.
The company claims to have successfully acquired and integrated seven hospitals, adding 1,650 beds across North India. These acquired hospitals contributed 54.24% to revenue from operations in the period ended September 30, 2024, 54.52% in FY24, 55.47% in FY23, and 53.58% in FY22. The company claims these hospitals to be quality assets with high turnaround potential.
The company is highly dependent on doctors, nurses, medical professionals, and support staff to operate its hospitals. As of September 30, 2024, it employed 891 doctors with an attrition rate of 44.77 percent, 1,912 nurses (30.38%), 671 medical professionals (32.08%), and 1,761 support staff (22.28%). Persistently high attrition would require higher replacement costs, disrupt continuity of care, and affect operational efficiency.
A substantial portion of revenue is concentrated in hospitals located in Haryana. Revenue from this state amounted to Rs 516.00 crore (74.62 percent) in the period ended September 30, 2024, Rs 946.98 crore (76.92 percent) in FY24, Rs 1,052.75 crore (83.91%) in FY23, and Rs 921.51 crore (84.98%) in FY22. Any operational disruptions, regulatory changes, or regional competition in Haryana may materially impact financial performance due to the limited diversification of revenue sources.
The business incurs high expenditure on materials, employee benefits, and professional fees. These costs totalled Rs 372.77 crore (66.57%) of total expenses in the period ended September 30, 2024, Rs 635.08 crore (60.97%) in FY24, Rs 547.17 crore (57.27%) in FY23, and Rs 412.22 crore (50.54%) in FY22. If these rising costs cannot be passed on through pricing adjustments, profitability and margins may be adversely impacted.
A major portion of revenue is derived from seven specialities, including internal medicine, neurology, urology, gastroenterology, cardiology, general surgery, and orthopaedics. The revenue from these specialities contributed Rs 637.35 crore (92.17%) to the total revenue in the period ended September 30, 2024; Rs 1,143.06 crore (92.87%) in FY24; Rs 1,159.39 crore (92.42%) in FY23; and Rs 980.19 crore (90.39%) in FY22. Furthermore, internal medicine alone contributed Rs 255.84 crore (37.00%) to the company’s revenue in the period ended September 30, 2024; Rs 464.07 crore (37.70%) in FY24; Rs 516.53 crore (41.17%) in FY23; and Rs 498.67 crore (45.99%) in FY22. Any decline in demand, policy changes, or pricing pressures in these specialities may have a disproportionately negative impact on revenue and financial results.
The company, its subsidiaries, directors, promoters, and senior and key management personnel are involved in certain ongoing legal proceedings. The legal proceedings include criminal proceedings, tax proceedings, statutory or regulatory proceedings, and material civil litigation. Any adverse judgment in these cases can be detrimental to the company’s business prospects.
The company depends significantly on revenue from its in-patient department. In-patient revenue accounted for Rs 665.20 crore (96.20%) in the period ended September 30, 2024, Rs 1,185.19 crore (96.27%) in FY24, Rs 1,221.24 crore (97.34%) in FY23, and Rs 1,040.36 crore (95.94%) in FY22. A decline in occupancy levels could reduce revenue utilisation from high capital-intensive hospital infrastructure and adversely impact profitability and operational efficiency.
A substantial portion of revenue is derived from payments by government schemes and PSUs. They contributed Rs 617.30 crore (89.27%) to the revenue in the period ended September 30, 2024, Rs 1,115.21 crore (90.59%) in FY24, Rs 1,158.88 crore (92.37%) in FY23, and Rs 916.45 crore (84.51%) in FY22. Delays, rejections, or disputes in claim settlement may adversely affect cash flows, working capital, and financial performance.
As of September 30, 2024, the company had trade receivables of Rs 544.81 crore, up from Rs 510.96 crore in FY24. Any failure to collect these receivables on time or at all can negatively impact the business and its financial condition.
The company may face medical negligence claims, disputes, and regulatory actions arising from alleged lapses in healthcare delivery, inaccurate results, or complications during treatment. Such incidents may lead to litigation costs, penalties, or damage to reputation.
The company operates in a highly regulated sector and is subject to multiple safety, healthcare, and environmental regulations. Ensuring compliance may result in additional operational costs, and any non-compliance could lead to penalties, inspections, or restrictions on operations. Changes in regulation or stricter enforcement may further increase compliance expenses and disrupt business operations, potentially impacting margins and cash flows.
The largest vendor accounted for Rs 83.51 crore (44.57%) of the company’s total purchases for the period ended September 30, 2024; Rs 118.65 crore (46.09%) in FY24; Rs 102.71 crore (45.68%) in FY23; and Rs 60.55 crore (33.19% in FY22. Any disruption in supplies from this supplier could adversely affect the company’s business and finances.
As of September 30, 2024, the company had contingent liabilities of Rs 664.33 crore. If any of these liabilities materialise, they could adversely affect the company’s financial condition, cash flows, and results of operations.
As of September 30, 2024, the company had outstanding financial indebtedness of Rs 593.63 crore. Any failure to service or repay these loans can harm the company’s operations and financial position.